Minneapolis
89°F
eEdition
News & Politics
Sports
Food & Culture
Business
Outdoors
Opinion
Things To Do
Obituaries
More of What Matters to Minnesota
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Minnesota State Top Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Lexeo Therapeutics, Inc. - Common Stock
(NQ:
LXEO
)
12.05
-0.13 (-1.07%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Lexeo Therapeutics, Inc. - Common Stock
Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights
May 09, 2024
From
Lexeo Therapeutics
Via
GlobeNewswire
Lexeo Therapeutics to Participate in Upcoming Investor Conferences
May 07, 2024
From
Lexeo Therapeutics
Via
GlobeNewswire
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
April 22, 2024
From
Lexeo Therapeutics
Via
GlobeNewswire
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy
April 16, 2024
From
Lexeo Therapeutics
Via
GlobeNewswire
Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing
March 13, 2024
Lexeo extends runway into 2027 with private placement co-led by Braidwell LP and Adage Capital Partners LP with participation from new and existing investors including RA Capital Management, Surveyor...
From
Lexeo Therapeutics
Via
GlobeNewswire
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
March 11, 2024
From
Lexeo Therapeutics
Via
GlobeNewswire
Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing
March 11, 2024
Lexeo extends runway into 2027 with private placement co-led by Braidwell LP and Adage Capital Partners LP, with participation from new and existing investors including RA Capital Management, Surveyor...
From
Lexeo Therapeutics
Via
GlobeNewswire
Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments
February 05, 2024
From
Lexeo Therapeutics
Via
GlobeNewswire
Lexeo Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
LEXEO Therapeutics
Via
GlobeNewswire
Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM)
December 18, 2023
From
LEXEO Therapeutics
Via
GlobeNewswire
Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights
December 11, 2023
From
LEXEO Therapeutics
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.